Short Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Declines By 56.6%

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the target of a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 53,200 shares, a drop of 56.6% from the February 28th total of 122,600 shares. Currently, 3.3% of the company’s shares are sold short. Based on an average daily volume of 395,000 shares, the short-interest ratio is currently 0.1 days.

Aptose Biosciences Stock Down 10.3 %

NASDAQ APTO opened at $3.32 on Friday. Aptose Biosciences has a 52 week low of $2.39 and a 52 week high of $51.61. The business has a 50 day moving average price of $4.57 and a 200-day moving average price of $7.52. The company has a market cap of $7.11 million, a price-to-earnings ratio of -1.12 and a beta of 1.14.

Wall Street Analyst Weigh In

Several brokerages have issued reports on APTO. Alliance Global Partners raised Aptose Biosciences to a “strong-buy” rating in a research note on Thursday, February 27th. HC Wainwright boosted their target price on shares of Aptose Biosciences from $2.00 to $6.00 and gave the company a “buy” rating in a research report on Friday. Finally, StockNews.com initiated coverage on shares of Aptose Biosciences in a report on Thursday. They issued a “sell” rating for the company. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $112.00.

Institutional Trading of Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Bleichroeder LP bought a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 2,500,000 shares of the biotechnology company’s stock, valued at approximately $563,000. Bleichroeder LP owned approximately 4.15% of Aptose Biosciences at the end of the most recent reporting period. 26.62% of the stock is owned by institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.